News | May 14, 2025
Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
Gelhaus has a proven track record of driving business growth
This recertification of Company's OECD GLP is testimony to company's unwavering commitment to maintain international quality standards at the facility
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
ekincare has raised a total funding of $22M since 2015 till date
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Subscribe To Our Newsletter & Stay Updated
